These findings were corroborated in clinical studies showing that despite being a strong inducer of IDO1, IFN-γ was effective in the therapy of ovarian carcinoma and bladder cancer [20], [21], [22]. The gene discussed is IDO1; the disease is ovarian carcinoma.